ArticleNature2020
CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers.
0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
193 citing papers in PubMed, 326 citations in OpenAlex.
- CRISPR-cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation.Functional & integrative genomics · 2026Review
- Article
- A Framework for Benchmarking Pathway Reconstruction Algorithms.bioRxiv : the preprint server for biology · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Benchmarking Ultra-Low Attachment and Photopatterned GelMA 3D Culture Platforms for Modeling Cancer Stemness in High-Grade Serous Ovarian Cancer.Biotechnology journal · 2026Article
- Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.bioRxiv : the preprint server for biology · 2026Article
- Synthetic lethality in cancer: mechanism exploration and therapeutic applications.Cell communication and signaling : CCS · 2026Review
- Physiologically relevant 3D CRISPR screening enhances mechanistic insight into chemical toxicity compared to 2D screening.Toxicology · 2026Article
- Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks.Genome medicine · 2026Article
- Functional CRISPR Screens Define Genetic Drivers for Cancer Transformation and Progression from Non-Cancerous Cells.International journal of molecular sciences · 2026Article
- Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets.Journal of translational medicine · 2026Article
- Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer.Science advances · 2026Review
- Hemizygous loss of helicases promotes genomic instability and cancer development.Science advances · 2026Article
- Applying microfluidic technology to interpret the tumor immune microenvironment and cancer immunotherapy.Cancer biology & medicine · 2026Review
- Organ-on-a-Chip Technology and Global Multi-Omics: Current Applications and Future Directions.MedComm · 2026Review
- A Coumarin Compound Derived From Zanthoxylum avicennae Reduces the Pathogenicity of Fusarium verticillioides by Directly Binding to and Inhibiting Glycoside Hydrolase 3 Activity.Molecular plant pathology · 2026Article
- Breast Cancer Multicellular Spheroid Models-A Tool for Studying Cancer Biology; a Possible Platform for Drug Screening and Personalized Medicine.International journal of molecular sciences · 2026Review
- Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer.Cancer cell · 2026Article
- Hexokinase detachment from mitochondria drives the Warburg effect to support compartmentalized ATP production.Nature metabolism · 2026Article
- Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival.Cell reports · 2025Article
133 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 1 country.
Kyuho HanDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA. kyuhohan@stanford.edu.ORCID http://orcid.org/0000-0003-4259-8736
Sarah E PierceProgram in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9145-9559
Amy LiDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Kaitlyn SpeesDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Gray R AndersonDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Jose A SeoaneDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3856-9177
Yuan-Hung LoDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Michael DubreuilDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Micah OlivasDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5315-6303
Roarke A KamberDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Michael WainbergDepartment of Computer Science, Stanford University, Stanford, CA, USA.
Kaja KostyrkoDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Marcus R KellyProgram in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.
Maryam YousefiDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Scott W SimpkinsDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
David YaoDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Keonil LeeDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Calvin J KuoProgram in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.
Peter K JacksonProgram in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.
Alejandro Sweet-CorderoDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9787-9351
Anshul KundajeDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Andrew J GentlesDepartments of Medicine and Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0941-9858
Christina CurtisDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0166-3802
Monte M WinslowDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5730-9573
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA. bassik@stanford.edu.ORCID http://orcid.org/0000-0001-5185-8427
Stanford University · USUniversity of California, San Francisco · USStanford Health Care · US
Funding
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MHigh-throughput systematic characterization of regulatory element functionUM1HG009436 · NHGRI · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C, GREENLEAF, WILLIAM JAMES · 2017 to 2021
$5.4MOrganoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7MUsing Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancerU01CA199216 · NCI · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C, JACKSON, PETER KENT · 2015 to 2019
$3.2MAccelerating drug development and repurposing using systematic genetic interactioDP2HD084069 · NICHD · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C · 2014 to 2014
$2.4MTRANSCRIPTION FACTORS IN INTESTINAL DIFFERENTIATION AND CANCERK00CA212433 · NCI · STANFORD UNIVERSITY · PI LO, YUAN-HUNG · 2017 to 2020
$345kNCI NIH HHS K00 CA212433NCI NIH HHS T32 CA009302NCI NIH HHS U01 CA199216NCI NIH HHS U01 CA217851NHGRI NIH HHS UM1 HG009436NICHD NIH HHS DP2 HD084069
Abstract
Cancer genomics studies have identified thousands of putative cancer driver genes
Indexed as
AdenocarcinomaAmino Acid MotifsAnimalsCarboxypeptidasesCell Culture TechniquesCell ProliferationCRISPR-Cas SystemsFemaleGenome, HumanHumansLung NeoplasmsMiceMolecular Targeted TherapyMutationPhenotypeReceptor, IGF Type 1carboxypeptidase DCarboxypeptidasesIGF1R protein, humanReceptor, IGF Type 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.